Meeting
2013 ASCO Annual Meeting
A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC).
Authors
Ewa Mrozek
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH
Ewa Mrozek , Robert Wesolowski , Maryam B. Lustberg , Rachel M. Layman , Yonghua Ling , Larry J. Schaaf , Mitch A. Phelps , S. Percy Ivy , Michael R. Grever , Charles L. Shapiro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT01238133
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1043)
DOI
10.1200/jco.2013.31.15_suppl.1043
Abstract #
1043
Poster Bd #
19B
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929.
First Author: Jyoti Mayadev
Poster
2022 ASCO Annual Meeting
Safety and tolerability of olaparib combined with breast radiotherapy in patients with triple-negative breast cancer: Final results of the RADIOPARP phase 1 trial.
First Author: Pierre Loap
Poster
2022 ASCO Annual Meeting
Phase I study of epacadostat in combination with sirolimus in advanced malignancy.
First Author: Chao Hui Huang
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan